Research ArticleMinireview
The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors SB269652 May Lead to a New Generation of Antipsychotic Drugs
Mario Rossi, Irene Fasciani, Francesco Marampon, Roberto Maggio and Marco Scarselli
Molecular Pharmacology March 6, 2017, mol.116.107607; DOI: https://doi.org/10.1124/mol.116.107607
Mario Rossi
1 Molecular Signaling Section, Laboratory of Bioorganic Chemistry, NIDDK, U.S.A.;
Irene Fasciani
2 Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy;
Francesco Marampon
2 Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy;
Roberto Maggio
2 Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy;
Marco Scarselli
3 Department of Translational Research and New Technologies in Medicine and Surgery, Pisa University
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleMinireview
The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors SB269652 May Lead to a New Generation of Antipsychotic Drugs
Mario Rossi, Irene Fasciani, Francesco Marampon, Roberto Maggio and Marco Scarselli
Molecular Pharmacology March 6, 2017, mol.116.107607; DOI: https://doi.org/10.1124/mol.116.107607
Research ArticleMinireview
The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors SB269652 May Lead to a New Generation of Antipsychotic Drugs
Mario Rossi, Irene Fasciani, Francesco Marampon, Roberto Maggio and Marco Scarselli
Molecular Pharmacology March 6, 2017, mol.116.107607; DOI: https://doi.org/10.1124/mol.116.107607
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement